While GLP-1 receptor agonist drugs have not yet had seismic effects on the food industry, the second wave, which should be better tolerated and easier to consume, is likely to drive wider adoption, predict experts. And food companies better be ready, said Dr. Kim Fisher, director of programs at the UC Davis Innovation Institute for Food and Health (IIFH).
Speaking at a discovery forum on GLP-1s hosted by IIFH in Sacramento, California earlier this week, she said: “There are over 100 clinical studies in the pipeline right now with about 40 in phase three, meaning we’ll see new things on the market in the next year or two, from weekly pills to monthly injections. The benefit of combination therapies [‘multi-agonist’ drugs that activate GLP-1, GIP, and glucagon receptors] is you have fewer side effects. This is a pivotal moment for the food industry.”
